First treatment for all genotypes of hepatitis C in pediatric patients approved
Mavyret tablets were approved last week by the Food and Drug Administration for the treatment of all six genotypes of hepatitis C virus (HCV) in teenagers.
Mavyret tablets were approved last week by the Food and Drug Administration for the treatment of all six genotypes of hepatitis C virus (HCV) in teenagers.
A McDonough, Georgia man who was the first to fight of a debilitating and deadly disease points out the reasons why “right to try” legislation that is being considered in North Carolina needs to succeed, according to a Washington Post op-ed piece.
SEP-363856 offers an innovative approach to the treatment of schizophrenia including the potential to be the first agent for the treatment of schizophrenia that does not bind to dopamine 2 (D2) receptors
Erlotinib Hydrochloride Tablets treat metastatic non-small cell lung and pancreatic cancers
First and only medicines approved for patients with either wild-type or hereditary transthyretin amyloid cardiomyopathy
The U.S. Food and Drug Administration is now requiring its strongest warning to be used on several of the most commonly used prescription insomnia medicines.
EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
If approved by the FDA, pexidartinib would be the first and only approved therapy for tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations, and not amenable to improvement with surgery
Aidoc now leads the way in FDA approved AI solutions for radiologists
POLYTECH Health & Aesthetics GmbH, a global leader in breast aesthetics, welcomes a recent statement by the FDA that textured breast implants will remain available in the US market, In opposition to the recent decision by the French health authority ANSM (Agence Nationale de Sécurité du Médicament) to ban 'macrotextured' and polyurethane coated implants from the French market.
A meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee will take place on June 11 and June 12.
The Food and Drug Administration has been asked to investigate the e-cigarette company JUUL and its claims that it helps people to stop smoking.
Pet lovers and veterinarians stay tuned. Texas-based SelenBio is soon to launch an effective breakthrough in helping to prevent gum disease in dogs and cats.
Optune®, a wearable, portable device from Novocure delivers Tumor Treating Fields (TTFields) to slow down or stop GBM cancer cells from dividing, and destroys the cancer without disrupting healthy, resting cells
KardiaMobile® is the Only Personal ECG that Delivers Multi-Dimensional Insight into a Patient's Heart
Ayala Pharmaceuticals, a clinical-stage company developing medicines for cancers that are genetically defined, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) for AL101, a potent and selective inhibitor of gamma secretase-mediated Notch signalling, for the treatment of ACC.
Food producers carried out 23 food or dietary supplement product recalls over the past month, according to the U.S. Food and Drug Administration.
GATTEX is the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS who are dependent on parenteral support (PS)